Plaintiff
1 case as plaintiff.
Neurent Medical Ltd is a privately held MedTech company headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts. Founded in 2015 by David Townley and Brian Shields, the company employs approximately 35 to 76 individuals and is venture-backed. Neurent Medical has raised substantial funding, including a €62.5 million ($74 million) Series C financing round in February 2026.
The company specializes in developing innovative treatments for chronic inflammatory sino-nasal diseases. Its primary product is the NEUROMARK® System, a minimally invasive device that utilizes proprietary Impedance Controlled Radiofrequency technology. This system is designed to precisely target and disrupt hyperactive posterior nasal nerves, providing relief from chronic rhinitis symptoms such as congestion, rhinorrhea, sneezing, and nasal itching. The NEUROMARK® System has received U.S. FDA clearance for its next-generation device and has a dedicated CPT code for reimbursement.
Neurent Medical demonstrates an active two-way patent litigation posture. The company has appeared as a plaintiff in one tracked case, Neurent Medical Ltd. v. Aerin Medical Inc. in the U.S. District Court for the District of Delaware, filed in September 2024. Simultaneously, it has been a defendant in one case, Unified Patents v. Neurent Medical Ltd, before the Patent Trial and Appeal Board (PTAB). This indicates that Neurent Medical is both asserting its patent rights and defending them against challenges.
Watchlist
Email-only, free, anonymous. We'll notify you when Neurent Medical Ltd files another patent-infringement lawsuit. One-click unsubscribe from any alert.
This is an active litigation case filed in the Delaware District Court, with Neurent Medical Ltd as the plaintiff and CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L. as the defendant.